Wave Life Sciences (WVE) AI Stock Analysis

• Market Cap: $2.62B
• Dividend Yield: N/A
• Average Volume (3M): 2.85M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: 103.75%
• EPS Growth: 33.84%
• Country: US
• Employees: 287
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 182,996,750
• 10 Day Avg. Volume: 2,330,708
• 30 Day Avg. Volume: 2,851,998
• PEG Ratio: -0.19
• Price to Book (P/B): 5.53
• Price to Sales (P/S): 67.10
• P/FCF Ratio: -15.29
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 45.99
• Enterprise Value/Gross Profit: 93.02
• Enterprise Value/Ebitda: -9.68
• 1Y Price Target: $32.57
• Price Target Upside: 133.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15
• EPS Forecast (FY): -1.3
• Revenue Forecast (FY): $42.68M

• Rating: 56 Neutral
• Price Target: $15.00 ▲(7.68% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held back primarily by weak financial performance (steep revenue decline, large losses, and heavy cash burn). Offsetting this, the latest earnings call points to strong clinical/program momentum and a runway into Q3 2028, while technical signals are moderately supportive and valuation remains constrained by negative earnings.

Positive Factors

Platform differentiation (SpiNA)

Wave’s SpiNA chemistry claims materially higher Ago2 loading and exposure versus benchmarks, implying greater potency and duration. A durable platform advantage can lower dosing frequency, raise clinical differentiation, improve development efficiency across programs and create a sustainable competitive moat for RNA medicines.

Strong cash runway

A multi-year cash runway supports execution of several clinical programs and planned registrational activities without immediate dilution pressure. This balance-sheet buffer gives management time to derisk data, pursue regulatory engagements and capture milestone upside before needing material additional financing.

Regained rights to WVE-006

Recovering WVE-006 rights is a structural shift: Wave controls registrational strategy and economics for a first-in-class RNA editing AATD asset. That enables direct FDA engagement on accelerated approval, potentially faster commercialization and greater long-term upside if confirmatory pathways are successfully negotiated.

Negative Factors

High cash burn

Sustained negative operating and free cash flow indicates the business is not self-funding and remains reliant on external capital or milestone receipts. Continued burn at this scale can force dilution, constrain strategic optionality and will pressure the balance sheet if clinical or partnership milestones are delayed or absent.

Revenue decline & milestone reliance

Revenue is volatile and concentrated in collaboration milestones; the Takeda termination caused a step decline. This structural dependence on timing of partner payments undermines predictable funding, increases execution risk and makes long-term planning and margin improvement more uncertain.

Rising expenses & widening losses

Operating expenses are growing while revenues have fallen, deepening net losses and producing very weak returns (ROE ~-76%). If clinical readouts fail or are delayed, continued high spend will further erode equity and heighten the need for external funding, increasing shareholder dilution risk.

Wave Life Sciences Business Overview & Revenue Model

Company Description

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.

How the Company Makes Money

Wave Life Sciences generates revenue primarily through the development and commercialization of its therapeutic products. The company secures funding through partnerships with larger pharmaceutical companies, which may involve upfront payments, milestone payments upon achieving specific development goals, and royalties on future sales. Additionally, Wave may receive grants and funding from government and research institutions aimed at supporting innovative medical research. Significant collaborations with industry leaders can enhance its financial stability and provide access to resources necessary for advancing its product pipeline.

Wave Life Sciences Financial Statement Overview

Summary

Financials are pressured by a sharp TTM revenue decline (~61% YoY) and large ongoing losses (TTM net loss ~-$204M) with heavy cash burn (TTM operating/free cash flow ~-$187M). The balance sheet is a relative positive with low leverage (TTM debt-to-equity ~0.16) and improved equity versus prior years, but continued losses remain a key risk.

Income Statement

TTM (Trailing-Twelve-Months) revenue fell sharply to about $42.7M (down ~61% versus the prior year), signaling weakening collaboration/other revenue momentum. Profitability remains deeply negative: operating losses and net losses are large (TTM net loss about $204M) and margins are strongly negative, reflecting a cost structure still far above the current revenue base. A positive is that reported gross profitability is very high in recent periods, but it has not translated into operating leverage, and earnings quality remains pressured by sustained heavy R&D/operating spend.

Balance Sheet

Leverage looks manageable on the surface with low debt relative to equity in the most recent periods (TTM debt-to-equity roughly 0.16; 2024 about 0.12), which reduces near-term balance-sheet risk. Equity has improved substantially versus earlier years (including a period with negative equity in 2022), suggesting capital raises and/or balance-sheet repair. The key weakness is ongoing losses driving very weak returns on equity (TTM return on equity around -76%), which can erode the balance sheet over time if cash burn persists.

Cash Flow

Cash generation is a major concern: operating cash flow and free cash flow are materially negative (TTM operating/free cash flow about -$187M), indicating heavy ongoing cash burn. Free cash flow deterioration versus the prior year is modest but still negative, and cash outflows remain broadly in line with reported losses (free cash flow roughly matches net loss), implying the business is not yet demonstrating a path to self-funding operations. This keeps financing dependence elevated for a development-stage biotech profile.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	42.73M	108.30M	113.31M	3.65M	40.96M
Gross Profit	0.00	108.30M	113.31M	3.65M	40.96M
EBITDA	-204.38M	-101.74M	-58.79M	-152.61M	-117.18M
Net Income	-204.38M	-97.01M	-57.51M	-161.82M	-122.25M
Balance Sheet
Total Assets	23.68M	352.21M	274.95M	146.39M	207.01M
Cash, Cash Equivalents and Short-Term Investments	602.07M	302.08M	200.35M	88.50M	150.56M
Total Debt	17.77M	25.40M	32.12M	37.61M	29.92M
Total Liabilities	17.20M	142.69M	235.32M	191.48M	174.51M
Stockholders Equity	518.36M	209.51M	39.63M	-45.09M	32.50M
Cash Flow
Free Cash Flow	-187.49M	-151.96M	-20.55M	-129.14M	-89.55M
Operating Cash Flow	-187.49M	-151.03M	-19.43M	-127.78M	-88.99M
Investing Cash Flow	-718.00K	-938.00K	-1.11M	-1.25M	-560.00K
Financing Cash Flow	488.24M	253.89M	132.53M	67.19M	55.83M

Wave Life Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.93
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WVE, the sentiment is Positive. The current price of 13.93 is above the 20-day moving average (MA) of 13.46, below the 50-day MA of 14.50, and above the 200-day MA of 9.61, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 51.86 is Neutral, neither overbought nor oversold. The STOCH value of 80.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WVE.

Wave Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	61 Neutral	$2.08B	55.18	15.02%	―	1128.17%	―
PGEN	59 Neutral	$1.34B	-2.71	-507.72%	―	59.20%	-155.65%
NUVB	59 Neutral	$2.03B	―	-52.49%	―	1137.19%	70.51%
ORIC	57 Neutral	$1.35B	―	-41.27%	―	―	4.29%
WVE	56 Neutral	$2.62B	-11.49	-86.51%	―	103.75%	33.84%
RAPP	56 Neutral	$1.38B	-10.78	-23.41%	―	―	-37.07%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Wave Life Sciences Corporate Events

Wave Life Sciences Highlights 2025 Results and Obesity Progress

On February 26, 2026, Wave Life Sciences reported fourth-quarter and full-year 2025 results, highlighting progress across its RNA-based pipeline and a strong cash position of $602.1 million as of December 31, 2025, providing runway into the third quarter of 2028. Interim data from the Phase 1 INLIGHT trial of obesity candidate WVE-007 showed GLP-1-like fat loss with muscle preservation after a single 240 mg dose, and the company plans to start a Phase 2a multidose trial in higher-BMI patients and additional obesity studies in 2026.

Wave is also advancing its RNA editing assets, including WVE-006 for AATD, where the RestorAATion-2 trial is fully enrolled through the 600 mg cohort with further data readouts expected in 2026 and regulatory feedback on a potential accelerated pathway anticipated mid-year. The company is preparing a 2026 clinical trial application for WVE-008 for PNPLA3 I148M liver disease, remains on track to file a 2026 NDA for Duchenne candidate WVE-N531, and reported that GSK selected a fourth collaboration program in January 2026, supporting ongoing milestone revenue potential.

The most recent analyst rating on (WVE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Regains WVE-006 Rights, Plans Accelerated Path

On February 2, 2026, Wave Life Sciences announced that it has regained full rights to WVE-006, its first-in-class GalNAc-conjugated RNA editing candidate for alpha-1 antitrypsin deficiency (AATD), from partner GSK, enabling the company to accelerate its registrational strategy for this rare disease asset. Wave said it plans to seek U.S. Food and Drug Administration feedback by mid-2026 on a potential accelerated approval pathway for WVE-006, which is designed to address both lung and liver manifestations of AATD and has shown a favorable safety profile to date, with additional data from the ongoing RestorAATion-2 trial’s 400 mg multidose cohort expected in the first quarter of 2026 and from 600 mg cohorts later in the year. The company’s broader collaboration with GSK remains in place and expanded in January 2026 with the selection of a fourth oligonucleotide program, under a deal that could yield up to $2.8 billion in milestones and royalties, while Wave reiterated that its current cash resources are expected to fund operations into the third quarter of 2028, underscoring a solid financial runway to advance its RNA medicines pipeline.

The most recent analyst rating on (WVE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences sets 2026 strategy, highlights obesity program

On January 12, 2026, Wave Life Sciences outlined its 2026 strategic priorities, centered on accelerating development of its investigational INHBE-targeting siRNA WVE-007 for obesity and advancing its RNA editing pipeline, while presenting at the 44th Annual J.P. Morgan Healthcare Conference. The company reported that 2025 single-dose data from the INLIGHT trial showed WVE-007 produced three-month fat loss comparable to GLP-1 therapies with preserved muscle and potential once- or twice-yearly dosing, and it plans to deliver additional higher-dose and longer follow-up data throughout 2026, initiate a Phase 2a multidose study in higher-BMI patients with comorbidities in the first half of 2026, and start new trials of WVE-007 as both an add-on to incretin drugs and as post-incretin maintenance. Wave highlighted continued progress in RNA editing with WVE-006 for alpha-1 antitrypsin deficiency, with further RestorAATion-2 data from higher-dose cohorts expected in 2026, and said it plans to file a clinical trial application in 2026 for WVE-008 targeting an estimated nine million individuals with homozygous PNPLA3 I148M liver disease in the U.S. and Europe. The company is also developing a bifunctional oligonucleotide modality that combines RNAi and RNA editing in a single construct, expects additional updates on this platform in 2026, and is advancing WVE-N531 toward a planned 2026 new drug application for Duchenne muscular dystrophy and preparing a potentially registrational Phase 2/3 program for Huntington’s disease candidate WVE-003, contingent on partnering. Wave reported preliminary, unaudited cash and cash equivalents of approximately $602 million as of December 31, 2025, supporting an expected cash runway into the third quarter of 2028, a level of funding that underpins its expanded clinical agenda and positions the company as an increasingly prominent player in competitive obesity and genetic liver and neuromuscular disease markets.

The most recent analyst rating on (WVE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Announces Public Offering for $402.5 Million

On December 9, 2025, Wave Life Sciences announced an underwritten public offering of 15,789,475 ordinary shares at $19.00 per share and pre-funded warrants for 2,631,578 shares at $18.9999 each, expecting gross proceeds of approximately $402.5 million. The offering, which includes an option for underwriters to purchase additional shares, is anticipated to close on December 11, 2025, and will support the company’s operations into the third quarter of 2028, enhancing its market positioning and financial stability.

The most recent analyst rating on (WVE) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.

Wave Life Sciences Announces Positive Phase 1 Trial Results

On December 8, 2025, Wave Life Sciences announced positive interim data from its Phase 1 INLIGHT trial for WVE-007, a treatment for obesity. The trial showed significant improvements in body composition, including reductions in visceral and total body fat and an increase in lean mass, with a favorable safety profile. These results suggest the potential for WVE-007 to be a transformative obesity treatment with once or twice-yearly dosing, addressing the limitations of current GLP-1 therapies. The company is planning Phase 2 trials and expects further data updates in 2026.

The most recent analyst rating on (WVE) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Wave Life Sciences stock, see the WVE Stock Forecast page.